Unrelated Donor Stem Cell Transplantation

Allogeneic Hematopoietic Progenitor Cell Transplantation From Unrelated Donors

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01364363

Enrollment

Registered

2011-06-02

Start date

2005-03-31

Completion date

2015-07-31

Last updated

2022-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Hodgkin's Lymphoma, Large Granulocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Syndromes, Non-Hodgkin's Lymphoma, Paroxysmal Nocturnal Hemoglobinuria, Severe Aplastic Anemia, Small Lymphocytic Lymphoma

Keywords

Transplant, Allogeneic, Allogeneic transplant, Unrelated donor transplant, MUD, HSCT, Stem cell transplant

Brief summary

The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.

Detailed description

same

Interventions

PROCEDUREAllogeneic transplantation

Allogeneic transplantation with matched unrelated donors

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 69 Years

Healthy volunteers

Inclusion criteria

* \> 18 years of Age * \< 70 years * ECOG performance status 0, 1 or 2 * Left Ventricular Ejection Fraction \> 30% * Creatinine clearance \> 40ml/min * Transaminases \< 2X normal * Total bilirubin \< 2X normal * HIV seronegativity * Weight \< 70kg for cord blood transplantation * Ability to cover the cost of the transplant, necessary medications, and transportation/housing. * Caregiver must be available while outpatient

Exclusion criteria

* Greater than one antigen mismatch at HLA-A, B, C or DR plus one allele mismatch at HLA-A, B, C or DR

Design outcomes

Primary

Measure	Time frame	Description
Bone Marrow and Peripheral Blood Chimerism	30 days post-transplant	Percent of donor and host cells in peripheral blood and bone marrow will be measured by short tandem repeat (STR) testing and/or standard cytogenetic testing.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026